Applied Therapeutics (NASDAQ:APLT) Trading 7.8% Higher

Applied Therapeutics, Inc. (NASDAQ:APLTGet Free Report) was up 7.8% during mid-day trading on Monday . The stock traded as high as $4.86 and last traded at $4.86. Approximately 26,523 shares traded hands during trading, a decline of 98% from the average daily volume of 1,580,578 shares. The stock had previously closed at $4.51.

Wall Street Analyst Weigh In

Several brokerages have commented on APLT. Royal Bank of Canada restated an “outperform” rating and set a $12.00 price objective on shares of Applied Therapeutics in a research report on Thursday, April 11th. UBS Group upped their price objective on Applied Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $11.00.

View Our Latest Stock Analysis on APLT

Applied Therapeutics Stock Performance

The company has a fifty day moving average of $4.50 and a two-hundred day moving average of $4.53. The company has a market cap of $558.78 million, a price-to-earnings ratio of -2.64 and a beta of 1.99.

Applied Therapeutics (NASDAQ:APLTGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $10.00 million. Equities analysts expect that Applied Therapeutics, Inc. will post -0.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Leslie D. Funtleyder sold 16,980 shares of Applied Therapeutics stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $4.32, for a total transaction of $73,353.60. Following the transaction, the chief financial officer now owns 291,441 shares in the company, valued at $1,259,025.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CFO Leslie D. Funtleyder sold 16,980 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $4.32, for a total transaction of $73,353.60. Following the completion of the transaction, the chief financial officer now directly owns 291,441 shares in the company, valued at $1,259,025.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Real Estate Equitie Alexandria sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $4.21, for a total value of $631,500.00. Following the completion of the sale, the insider now owns 6,005,077 shares in the company, valued at $25,281,374.17. The disclosure for this sale can be found here. Insiders have sold 250,778 shares of company stock valued at $1,066,861 in the last ninety days. 8.60% of the stock is currently owned by insiders.

Institutional Trading of Applied Therapeutics

A number of large investors have recently bought and sold shares of the business. Vontobel Holding Ltd. bought a new stake in shares of Applied Therapeutics during the 4th quarter valued at about $34,000. Jump Financial LLC bought a new stake in shares of Applied Therapeutics in the 4th quarter valued at $81,000. Denali Advisors LLC acquired a new position in shares of Applied Therapeutics during the 1st quarter valued at $228,000. EntryPoint Capital LLC acquired a new stake in Applied Therapeutics in the first quarter worth $272,000. Finally, Citigroup Inc. acquired a new position in shares of Applied Therapeutics during the third quarter valued at about $164,000. 98.31% of the stock is currently owned by institutional investors and hedge funds.

About Applied Therapeutics

(Get Free Report)

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

Further Reading

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.